SCHEMBL1815698

SCHEMBL1815698

COc1ccc(/C=C/c2ccc(O)cc2)cc1OC

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 7/20 0.79
PTGS1 P23219 2/20 0.79
PTGS2 P35354 2/20 0.79
MAPT P10636 3/20 0.74
APP P05067 3/20 0.74
CYP1B1 Q16678 6/20 0.70
CYP1A2 P05177 2/20 0.70
TUBB4A P04350 1/20 0.70
TUBB P07437 1/20 0.70
TUBA3C P0DPH7 1/20 0.70
TUBA1B P68363 1/20 0.70
TUBA4A P68366 1/20 0.70
TUBB4B P68371 1/20 0.70
TUBB3 Q13509 1/20 0.70
TUBB2A Q13885 1/20 0.70
TUBB8 Q3ZCM7 1/20 0.70
TUBA3E Q6PEY2 1/20 0.70
TUBA1A Q71U36 1/20 0.70
TUBA1C Q9BQE3 1/20 0.70
TUBB6 Q9BUF5 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30940355 1.00 CYP1A1 (0.79) CYP1A1PTGS1PTGS2MAPTAPP
SCHEMBL1815699 1.00 CYP1A1 (0.79) CYP1A1PTGS1PTGS2MAPTAPP
SCHEMBL9173377 0.90 CYP1A1 (0.84) CYP1A1PTGS1PTGS2MAPTAPP
SCHEMBL9173364 0.90 CYP1A1 (0.84) CYP1A1PTGS1PTGS2MAPTAPP
Rhapontigenin SCHEMBL10307426 0.89 CYP1A1 (1.00) CYP1A1PTGS1PTGS2MAPTAPP
Rhapontigenin SCHEMBL19433130 0.89 CYP1A1 (1.00) CYP1A1PTGS1PTGS2MAPTAPP
Rhapontigenin SCHEMBL31028358 0.89 CYP1A1 (1.00) CYP1A1PTGS1PTGS2MAPTAPP
SCHEMBL9431599 0.88 CYP1A1 (0.80) CYP1A1PTGS1PTGS2MAPTAPP
SCHEMBL9586847 0.88 CYP1A1 (0.80) CYP1A1PTGS1PTGS2MAPTAPP
SCHEMBL5315843 0.87 TTR (0.80) PTGS2MAPTAPPCYP1A2NFE2L2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3280402-B1 TOLAN COMPOUNDS FOR PROMOTING WOUND HEALING BIOMENDICS LLC (US) 2024-06-05 EP disclosed
EP-3212754-B1 METHOD OF PRESERVING WINE AND PRESERVED RED WINE RESWINE LLC (US) 2023-12-13 EP disclosed
US-20210228501-A1 Formulation and Process for Modulating Wound Healing BioMendics, LLC (US) 2021-07-29 US disclosed
US-10426742-B2 Formulation and process for modulating wound healing BioMendics, LLC (US) 2019-10-01 US disclosed
US-20190022029-A1 Formulation and Process for Modulating Wound Healing BioMendics, LLC (US) 2019-01-24 US disclosed
EP-2231847-B1 METHOD AND COMPOSITIONS FOR PRESERVING WINE RUBIN DAVID (US) 2018-10-31 EP disclosed
EP-3212754-A1 METHOD AND COMPOSITION OF PRESERVING WINE Reswine, LLC (US) 2017-09-06 EP disclosed
US-9752110-B2 Method and compositions of preserving wine YSDR, LLC (US) 2017-09-05 US disclosed
US-20160296477-A1 Formulation and Process for Modulating Wound Healing BioMendics, LLC (US) 2016-10-13 US disclosed
US-9422286-B2 Metal-binding bifunctional compounds as diagnostic agents for Alzheimer's disease WASHINGTON UNIVERSITY (US) 2016-08-23 US disclosed
US-9422286-B2 Metal-binding bifunctional compounds as diagnostic agents for Alzheimer's disease WASHINGTON UNIVERSITY (US) 2016-08-23 US disclosed
WO-2016069654-A1 METHOD AND COMPOSITION OF PRESERVING WINE YSDR, LLC (US) 2016-05-06 WO disclosed
US-20150209452-A1 METAL-BINDING BIFUNCTIONAL COMPOUNDS AS DIAGNOSTIC AGENTS FOR ALZHEIMER'S DISEASE WASHINGTON UNIVERSITY (US) 2015-07-30 US disclosed
US-20150209452-A1 METAL-BINDING BIFUNCTIONAL COMPOUNDS AS DIAGNOSTIC AGENTS FOR ALZHEIMER'S DISEASE WASHINGTON UNIVERSITY (US) 2015-07-30 US disclosed
US-20150044328-A1 METHOD AND COMPOSITIONS OF PRESERVING WINE Reswine, LLC 2015-02-12 US disclosed
US-8871284-B2 Method and compositions for preserving wine YSDR LLC (US) 2014-10-28 US disclosed
US-20110104328-A1 METHOD AND COMPOSITIONS FOR PERSERVING WINE Reswine, LLC 2011-05-05 US disclosed
US-20090175984-A1 METHOD AND COMPOSITIONS FOR PRESERVING WINE Reswine, LLC 2009-07-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150209452-A1 METAL-BINDING BIFUNCTIONAL COMPOUNDS AS DIAGNOSTIC AGENTS FOR ALZHEIMER'S DISEASE APBA1, PSEN2, PSEN1 CYP1A1 3802/4885PTGS1 3649/4885PTGS2 3146/4885
US-20160296477-A1 Formulation and Process for Modulating Wound Healing SQSTM1, ATG7, TFEB CYP1A1 3239/4885PTGS1 1421/4885PTGS2 2761/4885
US-20210228501-A1 Formulation and Process for Modulating Wound Healing ATG7, SQSTM1, ATF4 CYP1A1 2787/4885PTGS1 1642/4885PTGS2 2688/4885
US-10426742-B2 Formulation and process for modulating wound healing SQSTM1, ATG7, TFEB CYP1A1 3353/4885PTGS1 1684/4885PTGS2 2804/4885
US-20190022029-A1 Formulation and Process for Modulating Wound Healing SQSTM1, ATG7, TFEB CYP1A1 3353/4885PTGS1 1684/4885PTGS2 2804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.